Skip to main content
Top
Published in: Radiation Oncology 1/2018

Open Access 01-12-2018 | Research

Changes in cardiac volume determined with repeated enhanced 4DCT during chemoradiotherapy for esophageal cancer

Authors: Xue Wang, Jin-Zhi Wang, Jian-Bin Li, Ying-Jie Zhang, Feng-Xiang Li, Wei Wang, Yan-Luan Guo, Qian Shao, Min Xu, Xi-Jun Liu, Yue Wang

Published in: Radiation Oncology | Issue 1/2018

Login to get access

Abstract

Background

Concurrent chemoradiotherapy is considered curative intent treatment for patients with non-operative esophageal cancer. Radiation-induced heart damage receives much attention. We performed repeated four-dimensional computed tomography (4DCT) to detect changes in cardiac volume during radiotherapy for esophageal cancer patients, and explored potential factors responsible for those changes.

Methods

Forty-six patients with esophageal cancer underwent enhanced 4DCT and three-dimensional (3D) CT scans before radiotherapy and every 10 fractions during treatment. The heart was contoured on 3DCT images, 4DCT end expiratory (EE) images and 4DCT maximum intensity projection (MIP) images by the same radiation oncologist. Heart volumes and other relative parameters were compared by the SPSS software package, version 19.0.

Results

Compared with its initial value, heart volume was smaller at the 10th fraction (reduction = 3.27%, 4.45% and 4.52% on 3DCT, EE and MIP images, respectively, p < 0.05) and the 20th fraction (reduction = 6.05%, 5.64% and 4.51% on 3DCT, EE and MIP images, respectively, p < 0.05), but not at the 30th fraction. Systolic and diastolic blood pressures were reduced (by 16.95 ± 16.69 mmHg and 7.14 ± 11.64 mmHg, respectively, both p < 0.05) and the heart rate was elevated by 5.27 ± 6.25 beats/min (p < 0.05) after radiotherapy. None of the potential explanatory variables correlated with heart volume changes.

Conclusions

Cardiac volume reduced significantly from an early treatment stage and maintained the reduction until the middle stage. The heart volume changes observed on 3DCT and 4DCT were consistent during radiotherapy. The changes in heart volume, blood pressure and heart rate may be valuable indicators of cardiac impairment and target dose changes.
Literature
1.
go back to reference Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–27.CrossRef Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–27.CrossRef
2.
go back to reference Hatakenaka M, Yonezawa M, Nonoshita T, Nakamura K, Yabuuchi H, Shioyama Y, Nagao M, Matsuo Y, Kamitani T, Higo T, Nishikawa K, Setoguchi T, Honda H. Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation. Int J Radiat Oncol Biol Phys. 2012;83:e67–73.CrossRef Hatakenaka M, Yonezawa M, Nonoshita T, Nakamura K, Yabuuchi H, Shioyama Y, Nagao M, Matsuo Y, Kamitani T, Higo T, Nishikawa K, Setoguchi T, Honda H. Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation. Int J Radiat Oncol Biol Phys. 2012;83:e67–73.CrossRef
3.
go back to reference Zhang P, Hu X, Yue J, Meng X, Han D, Sun X, Yang G, Wang S, Wang X, Yu J. Early detection of radiation-induced heart disease using (99m) Tc-MIBI SPECT gated myocardial perfusion imaging in patients with oesophageal cancer during radiotherapy. Radiother Oncol. 2015;115:171–8.CrossRef Zhang P, Hu X, Yue J, Meng X, Han D, Sun X, Yang G, Wang S, Wang X, Yu J. Early detection of radiation-induced heart disease using (99m) Tc-MIBI SPECT gated myocardial perfusion imaging in patients with oesophageal cancer during radiotherapy. Radiother Oncol. 2015;115:171–8.CrossRef
4.
go back to reference Monjazeb AM, Blackstock AW. The impact of multimodality therapy of distal esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications. Semin Radiat Oncol. 2013;23:60–73.CrossRef Monjazeb AM, Blackstock AW. The impact of multimodality therapy of distal esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications. Semin Radiat Oncol. 2013;23:60–73.CrossRef
5.
go back to reference Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P, Lazzarino M. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12:6487–93.CrossRef Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P, Lazzarino M. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12:6487–93.CrossRef
6.
go back to reference Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer. 1976;37:2813–25.CrossRef Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer. 1976;37:2813–25.CrossRef
7.
go back to reference Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270:1949–55.CrossRef Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270:1949–55.CrossRef
8.
go back to reference Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.CrossRef Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.CrossRef
9.
go back to reference Konski A, Li T, Christensen M, Cheng JD, Yu JQ, Crawford K, Haluszka O, Tokar J, Scott W, Meropol NJ, Cohen SJ, Maurer A, Freedman GM. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol. 2012;104:72–7.CrossRef Konski A, Li T, Christensen M, Cheng JD, Yu JQ, Crawford K, Haluszka O, Tokar J, Scott W, Meropol NJ, Cohen SJ, Maurer A, Freedman GM. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol. 2012;104:72–7.CrossRef
10.
go back to reference Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, Komaki R, Liao Z. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70:707–14.CrossRef Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, Komaki R, Liao Z. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70:707–14.CrossRef
11.
go back to reference Cosset JM, Henry-Amar M, Pellae-Cosset B, Carde P, Girinski T, Tubiana M, Hayat M. Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys. 1991;21:447–9.CrossRef Cosset JM, Henry-Amar M, Pellae-Cosset B, Carde P, Girinski T, Tubiana M, Hayat M. Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys. 1991;21:447–9.CrossRef
12.
go back to reference Ogino I, Watanabe S, Iwahashi N, Kosuge M, Sakamaki K, Kunisaki C, Kimura K. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer. Strahlenther Onkol. 2016;192:359–67.CrossRef Ogino I, Watanabe S, Iwahashi N, Kosuge M, Sakamaki K, Kunisaki C, Kimura K. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer. Strahlenther Onkol. 2016;192:359–67.CrossRef
13.
go back to reference Haj Mohammad N, Kamphuis M, Hulshof MC, Lutkenhaus LJ, Gisbertz SS, Bergman JJ, de Bruin-Bon HA, Geijsen ED, Bel A, Boekholdt SM, van Laarhoven HW. Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer. Radiother Oncol. 2015;114:91–5.CrossRef Haj Mohammad N, Kamphuis M, Hulshof MC, Lutkenhaus LJ, Gisbertz SS, Bergman JJ, de Bruin-Bon HA, Geijsen ED, Bel A, Boekholdt SM, van Laarhoven HW. Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer. Radiother Oncol. 2015;114:91–5.CrossRef
14.
go back to reference Lutkenhaus LJ, Kamphuis M, van Wieringen N, Hulshof MC, Bel A. Reduction in cardiac volume during chemoradiotherapy for patients with esophageal cancer. Radiother Oncol. 2013;109:200–3.CrossRef Lutkenhaus LJ, Kamphuis M, van Wieringen N, Hulshof MC, Bel A. Reduction in cardiac volume during chemoradiotherapy for patients with esophageal cancer. Radiother Oncol. 2013;109:200–3.CrossRef
15.
go back to reference Wang JZ, Li JB, Qi HP, Li YK, Wang Y, Zhang YJ, Wang W. Effect of contrast enhancement in delineating GTV and constructing IGTV of thoracic oesophageal cancer based on 4D-CT scans. Radiother Oncol. 2016;119:172–8.CrossRef Wang JZ, Li JB, Qi HP, Li YK, Wang Y, Zhang YJ, Wang W. Effect of contrast enhancement in delineating GTV and constructing IGTV of thoracic oesophageal cancer based on 4D-CT scans. Radiother Oncol. 2016;119:172–8.CrossRef
16.
go back to reference Rietzel E, Pan T, Chen GT. Four-dimensional computed tomography: image formation and clinical protocol. Med Phys. 2005;32:874–89.CrossRef Rietzel E, Pan T, Chen GT. Four-dimensional computed tomography: image formation and clinical protocol. Med Phys. 2005;32:874–89.CrossRef
17.
go back to reference Keall P. 4-dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol. 2004;14:81–90.CrossRef Keall P. 4-dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol. 2004;14:81–90.CrossRef
18.
go back to reference Underberg RW, Lagerwaard FJ, Cuijpers JP, Slotman BJ, van Sörnsen de Koste JR, Senan S. Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:1283–90.CrossRef Underberg RW, Lagerwaard FJ, Cuijpers JP, Slotman BJ, van Sörnsen de Koste JR, Senan S. Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:1283–90.CrossRef
19.
go back to reference Guckenberger M, Wilbert J, Meyer J, Baier K, Richter A, Flentje M. Is a single respiratory correlated 4D-CT study sufficient for evaluation of breathing motion? Int J Radiat Oncol Biol Phys. 2007;67:1352–9.CrossRef Guckenberger M, Wilbert J, Meyer J, Baier K, Richter A, Flentje M. Is a single respiratory correlated 4D-CT study sufficient for evaluation of breathing motion? Int J Radiat Oncol Biol Phys. 2007;67:1352–9.CrossRef
20.
go back to reference Handels H, Werner R, Schmidt R, Frenzel T, Lu W, Low D, Ehrhardt J. 4D medical image computing and visualization of lung tumor mobility in spatio-temporal CT image data. I nt J Med Inform. 2007;76(Suppl 3):S433–9.CrossRef Handels H, Werner R, Schmidt R, Frenzel T, Lu W, Low D, Ehrhardt J. 4D medical image computing and visualization of lung tumor mobility in spatio-temporal CT image data. I nt J Med Inform. 2007;76(Suppl 3):S433–9.CrossRef
21.
go back to reference Dinkel J, Welzel T, Bolte H, Hoffmann B, Thierfelder C, Mende U, Debus J, Heller M, Kauczor HU, Biederer J. Four-dimensional multislice helical CT of the lung: qualitative comparison of retrospectively gated and static images in an ex-vivo system. Radiother Oncol. 2007;85:215–22.CrossRef Dinkel J, Welzel T, Bolte H, Hoffmann B, Thierfelder C, Mende U, Debus J, Heller M, Kauczor HU, Biederer J. Four-dimensional multislice helical CT of the lung: qualitative comparison of retrospectively gated and static images in an ex-vivo system. Radiother Oncol. 2007;85:215–22.CrossRef
22.
go back to reference Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–8.CrossRef Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–8.CrossRef
23.
go back to reference Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.CrossRef Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.CrossRef
24.
go back to reference Barjaktarovic Z, Schmaltz D, Shyla A, Azimzadeh O, Schulz S, Haagen J, Dörr W, Sarioglu H, Schäfer A, Atkinson MJ, Zischka H, Tapio S. PLoS One. 2011;6:e27811.CrossRef Barjaktarovic Z, Schmaltz D, Shyla A, Azimzadeh O, Schulz S, Haagen J, Dörr W, Sarioglu H, Schäfer A, Atkinson MJ, Zischka H, Tapio S. PLoS One. 2011;6:e27811.CrossRef
25.
go back to reference Chello M, Mastroroberto P, Romano R, Zofrea S, Bevacqua I, Marchese AR. Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg. 1996;4:222–6.CrossRef Chello M, Mastroroberto P, Romano R, Zofrea S, Bevacqua I, Marchese AR. Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg. 1996;4:222–6.CrossRef
26.
go back to reference Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.CrossRef Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.CrossRef
27.
go back to reference Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565–74.CrossRef Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565–74.CrossRef
28.
go back to reference Heidenreich PA, Hancock SL, Vagelos RH, Lee BK, Schnittger I. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150:977–82.CrossRef Heidenreich PA, Hancock SL, Vagelos RH, Lee BK, Schnittger I. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150:977–82.CrossRef
29.
go back to reference Edmunds K, Brooks C, Hansen VN, Harris V, Tait DM. Cardiac volume effects during chemoradiotherapy for esophageal cancer (regarding Lutkenhaus et al. reduction in cardiac volume during chemoradiotherapy for patients with esophageal cancer). Radiother Oncol. 2015;114:128–9.CrossRef Edmunds K, Brooks C, Hansen VN, Harris V, Tait DM. Cardiac volume effects during chemoradiotherapy for esophageal cancer (regarding Lutkenhaus et al. reduction in cardiac volume during chemoradiotherapy for patients with esophageal cancer). Radiother Oncol. 2015;114:128–9.CrossRef
30.
go back to reference Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70–5.CrossRef Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70–5.CrossRef
31.
go back to reference Martel MK, Sahijdak WM, Ten Haken RK, Kessler ML, Turrisi AT. Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys. 1998;40:155–61.CrossRef Martel MK, Sahijdak WM, Ten Haken RK, Kessler ML, Turrisi AT. Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys. 1998;40:155–61.CrossRef
32.
go back to reference Lee PJ, Mallik R. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. Cardiol Rev. 2005;13:80–6.CrossRef Lee PJ, Mallik R. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. Cardiol Rev. 2005;13:80–6.CrossRef
33.
go back to reference Camp-Sorrell D. Cardiovascular late effects. Oncology (Williston Park). 2008;22(2 Suppl Nurse Ed):42–4. Camp-Sorrell D. Cardiovascular late effects. Oncology (Williston Park). 2008;22(2 Suppl Nurse Ed):42–4.
34.
go back to reference Heidenreich PA, Kapoor JR. Radiation induced heart disease: systemic disorders in heart disease. Heart. 2009;95:252–8.CrossRef Heidenreich PA, Kapoor JR. Radiation induced heart disease: systemic disorders in heart disease. Heart. 2009;95:252–8.CrossRef
35.
go back to reference Cattaneo GM, Passoni P, Sangalli G, Slim N, Longobardi B, Mancosu P, Bettinardi V, Di Muzio N, Calandrino R. Internal target volume defined by contrast-enhanced 4D-CT scan in unresectable pancreatic tumour: evaluation and reproducibility. Radiother Oncol. 2010;97:525–9.CrossRef Cattaneo GM, Passoni P, Sangalli G, Slim N, Longobardi B, Mancosu P, Bettinardi V, Di Muzio N, Calandrino R. Internal target volume defined by contrast-enhanced 4D-CT scan in unresectable pancreatic tumour: evaluation and reproducibility. Radiother Oncol. 2010;97:525–9.CrossRef
36.
go back to reference Zhang P, Xi M, Li QQ, Hu YH, Guo X, Zhao L, Liu H, Liu SL, Luo LL, Liu Q, Liu MZ. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis. Oncotarget. 2016;7:44686–94.PubMedPubMedCentral Zhang P, Xi M, Li QQ, Hu YH, Guo X, Zhao L, Liu H, Liu SL, Luo LL, Liu Q, Liu MZ. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis. Oncotarget. 2016;7:44686–94.PubMedPubMedCentral
37.
go back to reference Kuropkat C, Griem K, Clark J, Rodriguez ER, Hutchinson J, Taylor SG 4th. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol. 1999;22:466–70.CrossRef Kuropkat C, Griem K, Clark J, Rodriguez ER, Hutchinson J, Taylor SG 4th. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol. 1999;22:466–70.CrossRef
38.
go back to reference Lieutaud T, Brain E, Golgran-Toledano D, Vincent F, Cvitkovic E, Leclercq B, Escudier B. 5-fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer. 1996;32A:368–9.CrossRef Lieutaud T, Brain E, Golgran-Toledano D, Vincent F, Cvitkovic E, Leclercq B, Escudier B. 5-fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer. 1996;32A:368–9.CrossRef
39.
go back to reference Schöber C, Papageorgiou E, Harstrick A, Bokemeyer C, Mügge A, Stahl M, Wilke H, Poliwoda H, Hiddemann W, Köhne-Wömpner CH. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 1993;72:2242–7.CrossRef Schöber C, Papageorgiou E, Harstrick A, Bokemeyer C, Mügge A, Stahl M, Wilke H, Poliwoda H, Hiddemann W, Köhne-Wömpner CH. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 1993;72:2242–7.CrossRef
40.
go back to reference Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105:48–51.CrossRef Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105:48–51.CrossRef
41.
go back to reference Içli F, Karaoğuz H, Dinçol D, Demirkazik A, Günel N, Karaoğuz R, Uner A. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587–93.CrossRef Içli F, Karaoğuz H, Dinçol D, Demirkazik A, Günel N, Karaoğuz R, Uner A. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587–93.CrossRef
Metadata
Title
Changes in cardiac volume determined with repeated enhanced 4DCT during chemoradiotherapy for esophageal cancer
Authors
Xue Wang
Jin-Zhi Wang
Jian-Bin Li
Ying-Jie Zhang
Feng-Xiang Li
Wei Wang
Yan-Luan Guo
Qian Shao
Min Xu
Xi-Jun Liu
Yue Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-018-1121-z

Other articles of this Issue 1/2018

Radiation Oncology 1/2018 Go to the issue